Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis.

@article{Cossburn2013ClinicalRO,
  title={Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis.},
  author={Mark D Cossburn and Katharine Elizabeth Harding and Gillian Ingram and Tariq M. El-Shanawany and Adrian Heaps and Trevor P Pickersgill and Stephen Jolles and Neil P. Robertson},
  journal={Neurology},
  year={2013},
  volume={80 1},
  pages={55-61}
}
OBJECTIVE Alemtuzumab is potentially a highly effective treatment for relapsing multiple sclerosis (MS) acting via complement-mediated lysis of circulating lymphocytes. Variability in posttreatment lymphocyte recovery time is observed, with some patients showing striking durability in the efficacy of treatment. This study aims to establish whether this observed variation affects clinical and imaging parameters of disease activity. METHODS A total of 56 patients were followed for a median of… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 10 times over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

Similar Papers

Loading similar papers…